PRINCETON, N.J., 31 July, 2021 -- KBP Biosciences Co., Ltd. (“KBP Biosciences” or the “Company”), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, is pleased to announce the appointment of Dr. Julia Yang as Chief Operating Officer of KBP Biosciences.
“We are delighted to have Dr. Julia Yang as our new COO. Her experience and expertise will add value to the business,” said Dr. Zhenhua Huang, Founder and Executive Chairman of KBP Biosciences. “Julia will collaborate with our senior executives and me in setting and driving organizational vision and strategy, and leading company-wide, cross functional programs and projects, with particular focus on global clinical development, clinical operation, Discovery, Chemistry, Manufacturing and Controls (CMC).”
Julia has 24 years of pharmaceutical/medical device experiences with managerial and supervisory experiences in Global Clinical Research & Drug Development, Global Medical Affairs and Global Business Development. She has proven track records in designing and leading global clinical programs (Phase I-IV and life cycle management) across multiple therapeutic areas, leading to NDA/MAA/BLA submissions, worldwide drug approvals and successful product launches globally (Praluent® for lipid lowering /cardiovascular, Fycompa® for anti-seizure, etc.). She also has proven ability in the new assets evaluation and due diligence that lead to successful mergers and acquisitions and international partnerships. Her extensive experience gained by working at global pharmaceutical companies including Sanofi, Baxter, Medtronic, Eisai and Amgen. Julia holds MD degree and Master of Business Administration (MBA) and completed her clinical /research fellowship training at Johns Hopkins University, School of Medicine and Mayo Clinic.
About KBP Biosciences
KBP Biosciences is a global, clinical-stage biotechnology company focused on discovering, developing, and commercializing innovative small-molecule therapeutics for the treatment of serious cardiorenal and infectious diseases with large unmet needs. Headquartered in Princeton, NJ, KBP Biosciences principally devotes its resources to major organ protection and anti-infectives therapeutic areas.
KBP Biosciences’ lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal Mineralocorticoid Receptor Antagonist (MRA) discovered and developed by KBP’s scientists, and is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, Chronic Kidney Disease (CKD) patients with uncontrolled hypertension. KBP Biosciences’ second product candidate, KBP-7072, a potentially best-in-class, potent, broad spectrum aminomethylcycline, is being developed as an anti-infective for Gram-positive, Gram-negative and anaerobic bacteria, including multi-drug resistant pathogens.
KBP Biosciences has built a proprietary small-molecule drug discovery platform to advance its pipeline of product candidates. The platform includes state-of-the-art processes for novel drug compound identification, high-volume screening and optimization, along with its substantial library of diverse chemical entities and select potential compounds. With its discovery platform, KBP Biosciences is able to generate a multitude of drug compounds and quickly identify the most promising differentiated and potent product candidates.
For more information about KBP Biosciences, please visit the company website at https://www.kbpbiosciences.com/
Contacts:
Investor Relations:
ir@kbpbiosciences.com
Public Relations:
pr@kbpbiosciences.com